{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:59:50Z","timestamp":1793818790177,"version":"4.6.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["CZ.02.1.01\/0.0\/0.0\/16_025\/0007397"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_025\/0007397"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","award":["86652036"],"award-info":[{"award-number":["86652036"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","award":["IGA_LF UP_2022_011"],"award-info":[{"award-number":["IGA_LF UP_2022_011"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004240","name":"Czech Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.cytogfr.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T17:01:16Z","timestamp":1650474076000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["IL-6 and its role in IgA nephropathy development"],"prefix":"10.1016","volume":"66","author":[{"given":"Yaroslava","family":"Groza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jemelkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona Raskova","family":"Kafkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Maly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Raska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","article-title":"Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients","volume":"180","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"issue":"6 Pt A","key":"10.1016\/j.cytogfr.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bbamcr.2016.03.018","article-title":"The role of interleukin-6 signaling in nervous tissue","volume":"1863","author":"Rothaug","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.cytogfr.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","article-title":"Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes","volume":"289","author":"Suzuki","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-potsdam study","volume":"52","author":"Spranger","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib5","first-page":"125","article-title":"Interleukin-6: a molecule with complex biological impact in cancer","volume":"34","author":"Lacina","year":"2019","journal-title":"Histol. Histopathol."},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nri2449","article-title":"Nutrient sensing and inflammation in metabolic diseases","volume":"8","author":"Hotamisligil","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/03009742.2018.1473488","article-title":"Increased B-cell activating factor, interleukin-6, and interleukin-8 in induced sputum from primary Sjogren\u2019s syndrome patients","volume":"48","author":"Nilsson","year":"2019","journal-title":"Scand. J. Rheumatol."},{"issue":"10","key":"10.1016\/j.cytogfr.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1089\/jir.2011.0029","article-title":"The dysregulation of cytokine networks in systemic lupus erythematosus","volume":"31","author":"Apostolidis","year":"2011","journal-title":"J. Interf. Cytokine Res.: Off. J. Int. S. Interf. Cytokine Res."},{"issue":"Suppl 2","key":"10.1016\/j.cytogfr.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02215851","article-title":"Cytokines in rheumatoid arthritis","volume":"14","author":"Houssiau","year":"1995","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg. Microb. Infect."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0014-5793(88)80766-X","article-title":"Recombinant human interleukin-6 (IL-6\/BSF-2\/HSF) regulates the synthesis of acute phase proteins in human hepatocytes","volume":"232","author":"Castell","year":"1988","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0014-5793(89)80476-4","article-title":"Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes","volume":"242","author":"Castell","year":"1989","journal-title":"FEBS Lett"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jcem.86.3.7305","article-title":"Circulating interleukin 6 levels blood pressure, and insulin sensitivity in apparently healthy men and women","volume":"86","author":"Fernandez-Real","year":"2001","journal-title":"J. Clin. Endocr. Metab."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.169.1.333","article-title":"The complex pattern of cytokines in serum from patients with meningococcal septic shock - association between Interleukin-6, Interleukin-1, and fatal outcome","volume":"169","author":"Waage","year":"1989","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113528","article-title":"The two-faced Cytokine IL-6 in host defense and diseases","volume":"19","author":"Narazaki","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphys.2019.01294","article-title":"Hepcidin and anemia: A tight relationship","volume":"10","author":"Pagani","year":"2019","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.20081571","article-title":"The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells","volume":"206","author":"Dienz","year":"2009","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017739","article-title":"IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation","volume":"6","author":"Eto","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V97.6.1817","article-title":"Interleukin-6 is a growth factor for nonmalignant human plasmablasts","volume":"97","author":"Jego","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4049\/jimmunol.148.2.404","article-title":"Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells","volume":"148","author":"Vernino","year":"1992","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.174.5.2720","article-title":"IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation","volume":"174","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1074-7613(00)00078-9","article-title":"Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1","volume":"13","author":"Diehl","year":"2000","journal-title":"Immunity"},{"issue":"7090","key":"10.1016\/j.cytogfr.2022.04.001_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20160417","article-title":"IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells","volume":"213","author":"Yang","year":"2016","journal-title":"J. Exp. Med."},{"issue":"Pt 1","key":"10.1016\/j.cytogfr.2022.04.001_bib25","first-page":"1","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.cytogfr.2022.04.001_bib27","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.4049\/jimmunol.143.9.2900","article-title":"Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies","volume":"143","author":"Hirata","year":"1989","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood.V84.7.2243.2243","article-title":"Identification of upstream signals regulating Interleukin-6 gene-expression during in-vitro treatment of human B-Cells with pokeweed mitogen","volume":"84","author":"Chauhan","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.166.4.967","article-title":"Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression","volume":"166","author":"Taga","year":"1987","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI115284","article-title":"Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis","volume":"88","author":"Fujihashi","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib31","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.183.4.1399","article-title":"The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6","volume":"183","author":"Peters","year":"1996","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.170.4.1409","article-title":"Soluble cytokine receptors are present in normal human urine","volume":"170","author":"Novick","year":"1989","journal-title":"J. Exp. Med."},{"issue":"18","key":"10.1016\/j.cytogfr.2022.04.001_bib33","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6.soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/CCM.0b013e318211ff56","article-title":"Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model","volume":"39","author":"Barkhausen","year":"2011","journal-title":"Crit. Care Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib36","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.4049\/jimmunol.159.3.1474","article-title":"Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice","volume":"159","author":"Peters","year":"1997","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2022.04.001_bib38","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/j.1460-2075.1995.tb07128.x","article-title":"A major role for the protein tyrosine kinase JAK1 in the JAK\/STAT signal transduction pathway in response to interleukin-6","volume":"14","author":"Guschin","year":"1995","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.cytogfr.2022.04.001_bib40","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J. Exp. Med."},{"issue":"22","key":"10.1016\/j.cytogfr.2022.04.001_bib41","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.271.22.12991","article-title":"Differential activation of acute phase response factor\/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation","volume":"271","author":"Gerhartz","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"Pt 2","key":"10.1016\/j.cytogfr.2022.04.001_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/bj20030708","article-title":"Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells","volume":"377","author":"Kretzschmar","year":"2004","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.24655","article-title":"Glucocorticoids increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor","volume":"55","author":"Dittrich","year":"2012","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cytogfr.2022.04.001_bib44","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.emboj.7601640","article-title":"Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor","volume":"26","author":"Irandoust","year":"2007","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.01.002","article-title":"gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis","volume":"15","author":"Bollrath","year":"2009","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.cytogfr.2022.04.001_bib46","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1096\/fj.04-3099fje","article-title":"STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells","volume":"19","author":"Jung","year":"2005","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib47","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1038\/s41598-017-08581-y","article-title":"Novel STAT binding elements mediate IL-6 regulation of MMP-1 and MMP-3","volume":"7","author":"Cutler","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1074-7613(00)80145-4","article-title":"Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis","volume":"11","author":"Shirogane","year":"1999","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/j.cytogfr.2022.04.001_bib49","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1093\/emboj\/17.22.6670","article-title":"STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition","volume":"17","author":"Fukada","year":"1998","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ni.1610","article-title":"The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat","volume":"9","author":"Manel","year":"2008","journal-title":"Nat. Immunol."},{"issue":"42","key":"10.1016\/j.cytogfr.2022.04.001_bib51","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1038\/sj.onc.1208788","article-title":"Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK\/STAT and FAK signalings in human hepatocellular carcinoma","volume":"24","author":"Niwa","year":"2005","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.cytogfr.2022.04.001_bib52","doi-asserted-by":"crossref","first-page":"16631","DOI":"10.1074\/jbc.272.26.16631","article-title":"Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase. Evidence for participation of multiple signaling pathways which converge at Ras","volume":"272","author":"Schiemann","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12964-019-0451-2","article-title":"The multi-site docking protein Grb2-associated binder 1 (Gab1) enhances interleukin-6-induced MAPK-pathway activation in an SHP2-, Grb2-, and time-dependent manner","volume":"17","author":"Bongartz","year":"2019","journal-title":"Cell Commun. Signal"},{"issue":"30","key":"10.1016\/j.cytogfr.2022.04.001_bib54","doi-asserted-by":"crossref","first-page":"20993","DOI":"10.1074\/jbc.M604208200","article-title":"Global gene expression analysis of ERK5 and ERK1\/2 signaling reveals a role for HIF-1 in ERK5-mediated responses","volume":"281","author":"Schweppe","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib55","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-13-3043","article-title":"ERK5 is a critical mediator of inflammation-driven cancer","volume":"75","author":"Finegan","year":"2015","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.cytogfr.2022.04.001_bib56","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1038\/sj.onc.1202738","article-title":"Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3","volume":"18","author":"Zauberman","year":"1999","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib57","first-page":"58","article-title":"Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer","volume":"1","author":"Johnson","year":"2012","journal-title":"Transl. Gastrointest Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib58","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/art.38245","article-title":"The p38-mediated rapid down-regulation of cell surface gp130 expression impairs interleukin-6 signaling in the synovial fluid of juvenile idiopathic arthritis patients","volume":"66","author":"Honke","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","article-title":"Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha","volume":"7","author":"Alessi","year":"1997","journal-title":"Curr. Biology: CB"},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/01.CIR.103.4.555","article-title":"Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase\/Akt phosphorylation and Bcl-xL\/caspase-3 interaction","volume":"103","author":"Negoro","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib61","doi-asserted-by":"crossref","first-page":"C487","DOI":"10.1152\/ajpcell.00112.2017","article-title":"Acute myotube protein synthesis regulation by IL-6-related cytokines","volume":"313","author":"Gao","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"7541","key":"10.1016\/j.cytogfr.2022.04.001_bib62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14228","article-title":"A gp130-Src-YAP module links inflammation to epithelial regeneration","volume":"519","author":"Taniguchi","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.210773.112","article-title":"The Hippo pathway: Regulators and regulations","volume":"27","author":"Yu","year":"2013","journal-title":"Genes Dev."},{"issue":"Pt 7","key":"10.1016\/j.cytogfr.2022.04.001_bib64","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1242\/jcs.075796","article-title":"Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF","volume":"124","author":"Tamm","year":"2011","journal-title":"J. Cell Sci."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib65","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/eji.1830221110","article-title":"High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo","volume":"22","author":"Lu","year":"1992","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib66","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","article-title":"Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia","volume":"78","author":"Klein","year":"1991","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cytogfr.2022.04.001_bib67","doi-asserted-by":"crossref","first-page":"15460","DOI":"10.18632\/oncotarget.7102","article-title":"Potential therapeutic implications of IL-6\/IL-6R\/gp130-targeting agents in breast cancer","volume":"7","author":"Heo","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib68","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/nbt1166","article-title":"Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains","volume":"23","author":"Silverman","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm811","article-title":"Cytokine traps: Multi-component, high-affinity blockers of cytokine action","volume":"9","author":"Economides","year":"2003","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.cytogfr.2022.04.001_bib70","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1002\/j.1460-2075.1994.tb06931.x","article-title":"Rational design of a receptor super-antagonist of human interleukin-6","volume":"13","author":"Savino","year":"1994","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib71","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"50","key":"10.1016\/j.cytogfr.2022.04.001_bib72","doi-asserted-by":"crossref","first-page":"42959","DOI":"10.1074\/jbc.M111.295758","article-title":"Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor","volume":"286","author":"Garbers","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib73","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib74","first-page":"565","article-title":"Cytokine production, serum levels and disease activity in systemic lupus erythematosus","volume":"18","author":"Grondal","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/096120339600500603","article-title":"Serum and urinary interleukin-6 in systemic lupus erythematosus","volume":"5","author":"Peterson","year":"1996","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1191\/096120398678919949","article-title":"Renal expression of IL-6 and TNFalpha genes in lupus nephritis","volume":"7","author":"Herrera-Esparza","year":"1998","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib77","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0046-8177(95)90253-8","article-title":"Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients","volume":"26","author":"Malide","year":"1995","journal-title":"Human Pathol."},{"issue":"9","key":"10.1016\/j.cytogfr.2022.04.001_bib78","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.4049\/jimmunol.0802412","article-title":"IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation","volume":"182","author":"Garaud","year":"2009","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib79","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","article-title":"Elevated tear interleukin-6 levels in patients with Sjogren syndrome","volume":"105","author":"Tishler","year":"1998","journal-title":"Ophthalmology"},{"issue":"16","key":"10.1016\/j.cytogfr.2022.04.001_bib80","doi-asserted-by":"crossref","first-page":"13740","DOI":"10.1074\/jbc.M210689200","article-title":"Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes","volume":"278","author":"Senn","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-pathol-011110-130216","article-title":"IgA nephropathy: Molecular mechanisms of the disease","volume":"8","author":"Mestecky","year":"2013","journal-title":"Annu. Rev. Pathol."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib83","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00018-012-1082-6","article-title":"Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma","volume":"70","author":"Stuchlova Horynova","year":"2013","journal-title":"Cell Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.cytogfr.2022.04.001_bib84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/glycob\/cwz007","article-title":"IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2","volume":"29","author":"Stewart","year":"2019","journal-title":"Glycobiology"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib85","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/glycob\/cwaa111","article-title":"Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases","volume":"31","author":"Stewart","year":"2021","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jmb.2007.03.002","article-title":"Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells","volume":"369","author":"Raska","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib87","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib88","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2016.07.011","article-title":"IgA nephropathy enigma","volume":"172","author":"Mestecky","year":"2016","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2022.04.001_bib89","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib90","first-page":"701","article-title":"Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy, nephrology, dialysis, transplantation: official publication of the european dialysis and transplant association","volume":"12","author":"Allen","year":"1997","journal-title":"Eur. Ren. Assoc."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib91","first-page":"629","article-title":"IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1","volume":"118","author":"Suzuki","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib92","first-page":"234","volume":"30","author":"Stuchlova Horynova","year":"2015","journal-title":"Eur. Ren. Assoc."},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib93","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1902\/jop.2014.140212","article-title":"Origin of galactose-deficient immunoglobulin g in gingival crevicular fluid in periodontitis","volume":"85","author":"Komiyama","year":"2014","journal-title":"J. Periodontol."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib94","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1681\/ASN.V104760","article-title":"Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy","volume":"10","author":"Hiki","year":"1999","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib95","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1523-1755.2001.060003969.x","article-title":"Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients","volume":"60","author":"Allen","year":"2001","journal-title":"Kidney Inte."},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib96","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis","volume":"93","author":"Suzuki","year":"2018","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib97","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib98","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1681\/ASN.2014101044","article-title":"Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy","volume":"27","author":"Huang","year":"2016","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib99","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy","volume":"19","author":"Gharavi","year":"2008","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.cytogfr.2022.04.001_bib100","first-page":"625A","article-title":"Effect of gp130 cytokines on IgA1-producing cells from patients with IgA nephropathy","volume":"22","author":"Yamada","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib101","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.ekir.2017.07.002","article-title":"Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy","volume":"2","author":"Yamada","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib102","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000505748","article-title":"Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy","volume":"6","author":"Yamada","year":"2020","journal-title":"Kidney Dis."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib103","first-page":"3451","article-title":"IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association","volume":"26","author":"Novak","year":"2011","journal-title":"Eur. Ren. Assoc."},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib104","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ki.2012.192","article-title":"The IgA1 immune complex-mediated activation of the MAPK\/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy","volume":"82","author":"Tamouza","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib105","series-title":"Molecular and Genetic Basis of Renal Disease","first-page":"481","article-title":"The molecular basis of IgA nephropathy","author":"Hsu","year":"2008"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000059327","article-title":"Selective induction of MCP-1 in human mesangial cells by the IL-6\/sIL-6R complex","volume":"8","author":"Coletta","year":"2000","journal-title":"Exp. Nephrol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib107","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/ki.1994.302","article-title":"Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6","volume":"46","author":"van den Dobbelsteen","year":"1994","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.cytogfr.2022.04.001_bib108","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1681\/ASN.2004111006","article-title":"Engagement of transferrin receptor by polymeric IgA1: Evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy","volume":"16","author":"Moura","year":"2005","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib109","first-page":"58","article-title":"Induction of interleukin 6 synthesis in mouse glomeruli and cultured mesangial cells","volume":"62","author":"Iwano","year":"1992","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib110","first-page":"991","article-title":"Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells","volume":"138","author":"Zoja","year":"1991","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1681\/ASN.V6195","article-title":"Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells","volume":"6","author":"Moriyama","year":"1995","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib112","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3346\/jkms.2002.17.2.208","article-title":"Effects of high glucose on interleukin-6 production in human mesangial cells","volume":"17","author":"Ihm","year":"2002","journal-title":"J. Korean Med. Sci."},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib113","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.4049\/jimmunol.153.11.5247","article-title":"Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation","volume":"153","author":"Gomez-Guerrero","year":"1994","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.cytogfr.2022.04.001_bib114","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","article-title":"IgG1 plasmacytosis in interleukin 6 transgenic mice","volume":"86","author":"Suematsu","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"kuwataInterleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib116","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4049\/jimmunol.1302249","article-title":"The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy","volume":"193","author":"Schmitt","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1440-1797.2008.01051.x","article-title":"Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy","volume":"14","author":"Stangou","year":"2009","journal-title":"Nephrology"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib118","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0971-4065.159303","article-title":"Th1, Th2 and Treg\/T17 cytokines in two types of proliferative glomerulonephritis","volume":"26","author":"Stangou","year":"2016","journal-title":"Indian J. Nephrol."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib119","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: An update","volume":"8","author":"Su","year":"2017","journal-title":"Front. Immunol."},{"issue":"3\u20134","key":"10.1016\/j.cytogfr.2022.04.001_bib120","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1159\/000345151","article-title":"Podocytes express IL-6 and lipocalin 2\/ neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury","volume":"121","author":"Lee","year":"2012","journal-title":"Nephron. Exp. Nephrol."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib121","doi-asserted-by":"crossref","first-page":"F945","DOI":"10.1152\/ajprenal.00423.2007","article-title":"Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy","volume":"294","author":"Lai","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib122","doi-asserted-by":"crossref","first-page":"F1683","DOI":"10.1152\/ajprenal.00512.2017","article-title":"Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis, American journal of physiology","volume":"315","author":"Wright","year":"2018","journal-title":"Ren. Physiol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib123","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-3083.1994.tb03448.x","article-title":"Interleukin-6 and interleukin-6 receptor are expressed by cultured glomerular epithelial cells","volume":"40","author":"Moutabarrik","year":"1994","journal-title":"Scand. J. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib124","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbrc.2013.05.046","article-title":"Sequential signaling cascade of IL-6 and PGC-1alpha is involved in high glucose-induced podocyte loss and growth arrest","volume":"435","author":"Kim","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib125","first-page":"26","article-title":"Human renal tubular cells as a cytokine source: PDGF-B, GM-CSF and IL-6 mRNA expression in vitro","volume":"1","author":"Frank","year":"1993","journal-title":"Exp. Nephrol."},{"issue":"5\u20136","key":"10.1016\/j.cytogfr.2022.04.001_bib126","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000020622","article-title":"Tubular epithelial cells: A critical cell type in the regulation of renal inflammatory processes","volume":"7","author":"van Kooten","year":"1999","journal-title":"Exp. Nephrol."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib127","doi-asserted-by":"crossref","first-page":"6357046","DOI":"10.1155\/2020\/6357046","article-title":"CD154 Induces Interleukin-6 Secretion by Kidney Tubular Epithelial Cells under Hypoxic Conditions: Inhibition by Chloroquine","volume":"2020","author":"Dewitte","year":"2020","journal-title":"Mediat. Inflamm."},{"issue":"6","key":"10.1016\/j.cytogfr.2022.04.001_bib128","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/ki.1996.521","article-title":"Urinary IL-6\/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy","volume":"50","author":"Ranieri","year":"1996","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib129","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1159\/000065465","article-title":"Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study","volume":"92","author":"Harada","year":"2002","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib130","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5414\/CN106983","article-title":"Urinary interleukin-6 (IL-6) and transforming growth factor (TGF-beta) levels in corticosteroidtreated patients with IgA nephropathy","volume":"76","author":"Kalliakmani","year":"2011","journal-title":"Clin. Nephrol."},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5414\/CN107836","article-title":"Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine","volume":"80","author":"Stangou","year":"2013","journal-title":"Clin. Nephrol."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib132","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.nefro.2016.11.017","article-title":"Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor beta1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy","volume":"37","author":"Segarra-Medrano","year":"2017","journal-title":"Nefrologia: Pub. Oficial De la Sociedad Espanola Nefrologia"},{"issue":"11","key":"10.1016\/j.cytogfr.2022.04.001_bib133","first-page":"1545","article-title":"Intrarenal cytokine mRNA expression and location in normal and IgA nephropathy tissue: TGF alpha, TGF beta, IGF 1, IL-4 and IL-6, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association","volume":"9","author":"Ballardie","year":"1994","journal-title":"Eur. Ren. Assoc."},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib134","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2169\/internalmedicine.34.1181","article-title":"Glomerular localization of interleukin-6 suppressed by steroid mini-pulse therapy in an IgA nephropathy patient","volume":"34","author":"Taniguchi","year":"1995","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2022.04.001_bib135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000045254","article-title":"Interleukin-6 localization and the prognosis of IgA nephropathy","volume":"81","author":"Taniguchi","year":"1999","journal-title":"Nephron"},{"key":"10.1016\/j.cytogfr.2022.04.001_bib136","first-page":"60","article-title":"Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system","volume":"72","author":"Novak","year":"2011","journal-title":"Adv. Otorhinolaryngol."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib137","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","article-title":"TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy","volume":"97","author":"Makita","year":"2020","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.cytogfr.2022.04.001_bib138","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1681\/ASN.2007121311","article-title":"Toll-like receptor 9 affects severity of IgA nephropathy","volume":"19","author":"Suzuki","year":"2008","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib139","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","article-title":"Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions","volume":"76","author":"Shuai","year":"1994","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cytogfr.2022.04.001_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.cytogfr.2022.04.001_bib141","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/emboj\/16.5.989","article-title":"1.9 A crystal structure of interleukin 6: Implications for a novel mode of receptor dimerization and signaling","volume":"16","author":"Somers","year":"1997","journal-title":"EMBO J."},{"issue":"5628","key":"10.1016\/j.cytogfr.2022.04.001_bib142","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1126\/science.1083901","article-title":"Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex","volume":"300","author":"Boulanger","year":"2003","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.cytogfr.2022.04.001_bib143","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1110\/ps.041117105","article-title":"Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane","volume":"14","author":"Schroers","year":"2005","journal-title":"Protein Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2022.04.001_bib144","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1084\/jem.167.2.332","article-title":"The essential role of B cell stimulatory factor 2 (BSF-2\/IL-6) for the terminal differentiation of B cells","volume":"167","author":"Muraguchi","year":"1988","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2022.04.001_bib145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3389\/fonc.2020.00928","article-title":"A potential role of YAP\/TAZ in the interplay between metastasis and metabolic alterations","volume":"10","author":"Yamaguchi","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610122000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610122000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:01:13Z","timestamp":1778601673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610122000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":145,"alternative-id":["S1359610122000235"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2022.04.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-6 and its role in IgA nephropathy development","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}